Vildagliptin

CAT: 0804-HY-14291-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14291-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].
CAS Number
[274901-16-5]
Product Name Alternative
LAF237; NVP-LAF 237
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Dipeptidyl Peptidase; Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Vildagliptin.html
Purity
99.93
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
O[C@@]1(C2)C[C@H]3C[C@H](C[C@]2(NCC(N4[C@H](C#N)CCC4)=O)C3)C1
Molecular Formula
C17H25N3O2
Molecular Weight
303.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
DPP-4

Alternative Products

CatalogName
M13841-01Vildagliptin
RM-V163214-01Hydroxy Vildagliptin
TRC-V305002-0.5MGVildagliptin-d3

Popular Products